186953-56-0
Chemical Structure
Pafuramidine
Synonym(s): DB289
- CAS No.: 186953-56-0
- Formula:C20H20N4O3
- Molecular Weight:364.40
IUPAC Name: 4,4'-(furan-2,5-diyl)bis(N-methoxybenzimidamide)
InChIKey: UKOQVLAXCBRRGH-UHFFFAOYSA-N
SMILES: N=C(C1=CC=C(C2=CC=C(C3=CC=C(C(NOC)=N)C=C3)O2)C=C1)NOC
Biological Activity: Pafuramidine (DB289) is an orally active proagent of Furamidine (HY-110137A). Pafuramidine is a potent anti-parasitic agent, can be used to research trypanosomiasis, Pneumocystis pneumonia and malaria[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Pafuramidine | 99.28% | Pafuramidine (DB289) is an orally active proagent of Furamidine (HY-110137A). Pafuramidine is a potent anti-parasitic agent, can be used to research trypanosomiasis, Pneumocystis pneumonia and malaria. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Pafuramidine (Standard) | ≥98% | Pafuramidine (Standard) is the analytical standard of Pafuramidine. This product is intended for research and analytical applications. Pafuramidine (DB289) is an orally active proagent of Furamidine (HY-110137A). Pafuramidine is a potent anti-parasitic agent, can be used to research trypanosomiasis, Pneumocystis pneumonia and malaria. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Mdachi RE, et al. Efficacy of the novel diamidine compound 2,5-Bis(4-amidinophenyl)- furan-bis-O-Methlylamidoxime (Pafuramidine, DB289) against Trypanosoma brucei rhodesiense infection in vervet monkeys after oral administration. Antimicrob Agents Chemother. 2009 Mar;53(3):953-7. [Content Brief]
- [2]. Pohlig G, et al. Efficacy and Safety of Pafuramidine versus Pentamidine Maleate for Treatment of First Stage Sleeping Sickness in a Randomized, Comparator-Controlled, International Phase 3 Clinical Trial. PLoS Negl Trop Dis. 2016 Feb 16;10(2):e0004363. [Content Brief]
- [3]. Chen D, et al. Pafuramidine for Pneumocystis jiroveci pneumonia in HIV-infected individuals. Expert Rev Anti Infect Ther. 2007 Dec;5(6):921-8. [Content Brief]
Keywords